Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with reduced kidney function have a higher risk of heart disease and death. Studies have shown that blood vessels in patients with hypertension change with a decrease of lumen size and growth of the vessel wall. By treating patients with antihypertensive certain medication vessel lumen and walls normalize. Treating hypertension in patients with chronic kidney disease slows the progression of kidney function loss.

The aim is to compare different degrees of antihypertensive medication in patients with chronic kidney disease and hypertension will slow the progression of kidney loss.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Pressure in Dialysis Patients

NCT01421771

Hypertension Renal Failure Chronic Requiring Hemodialysis Blood Pressure +1 more

COMPLETED NA

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

NCT05732727

Chronic Kidney Disease(CKD) Uncontrolled Hypertension

RECRUITING PHASE3

The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects

NCT02527837

Hypertension

UNKNOWN PHASE1

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

NCT00345150

Hypertension

COMPLETED PHASE1

Potassium Supplementation in CKD

NCT03253172

Renal Insufficiency, Chronic Potassium Depletion Hypertension +1 more

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Insufficiency Hypertension Vasodilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard treatment

Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.

Group Type ACTIVE_COMPARATOR

Beta-blocker, ACE-inhibitor

Intervention Type DRUG

Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day

Intensive vasodilation

Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months

Group Type ACTIVE_COMPARATOR

Calcium Channel Blockers, ACE-Inhibitor

Intervention Type DRUG

Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beta-blocker, ACE-inhibitor

Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day

Intervention Type DRUG

Calcium Channel Blockers, ACE-Inhibitor

Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* eGFR 15-60 ml/min for at least 3 months
* Blood pressure \> 130 mmHg systolic og \>80 mmHg diastolic (patients without antihypertensive treatment or in treatment with Beta-blockers, ACEi, ARBs or CCB not in maximum dosi).
* Blood pressure \< 130 mmHg systolic og \< 80 mmHg diastolic (patients receiving Beta-blockers, ACEi, ARBs og CCB).
* Fertile women using safe contraceptives

Exclusion Criteria

* Ultrasound verified Polycystic Kidney Disease (ADPKD)
* Claustrophobia (MRi scan).
* Contraindications to MRi.
* Pregnancy or wish to become pregnant in the study period.
* Nephrotic syndrome with gross edema.
* Known allergy to any study medication.
* Blood pressure \< 130 mmHg systolic or \< 80 mmHg diastolic without antihypertensive treatment.
* Blood pressure \> 130 mmHg systolic or \> 80 mmHg diastolic and in maximum dosages of all three Beta-blockers, ACEi (ARBs) and CCB.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes